PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-19.78%
Both yoy net incomes decline, with AXSM at -25.09%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
2.78%
Some D&A expansion while AXSM is negative at -0.04%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
37.14%
SBC growth while AXSM is negative at -30.84%. John Neff would see competitor possibly controlling share issuance more tightly.
172.06%
Well above AXSM's 159.88% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
172.06%
Growth well above AXSM's 147.42%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-10743.19%
Both negative yoy, with AXSM at -24.95%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-10.71%
Negative yoy CFO while AXSM is 16.73%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.75%
We cut debt repayment yoy while AXSM is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.18%
Both yoy lines negative, with AXSM at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.